

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number		10541216
Filing Date		2005-06-29
First Named Inventor	Mark Tawa	
Art Unit	1615	
Examiner Name	Eric Silverman	
Attorney Docket Number	TPIP017D/WO US	

U.S. PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	4008321		1977-02-15	Kamishita et al.	
	2	4853379		1989-08-01	Shroot et al.	
	3	5273760		1993-12-28	Oshlack et al.	
	4	5286493		1994-02-15	Oshlack et al.	
	5	5324351		1994-06-28	Oshlack et al.	
	6	5356467		1994-10-18	Oshlack et al.	
	7	5466823		1995-11-14	Talley et al.	
	8	5472712		1995-12-05	Oshlack et al.	

/Renee Claytor/

12/21/2009

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10541216
Filing Date		2005-06-29
First Named Inventor	Mark Tawa	
Art Unit		1615
Examiner Name	Eric Silverman	
Attorney Docket Number		TPIP017D/WO US

	9	5510496		1996-04-23	Talley et al.	
	10	5563165		1996-10-08	Talley et al.	
	11	5641512		1997-06-24	Cimiluca, P.	
	12	5753688		1998-05-19	Talley et al.	
	13	5760068		1998-06-02	Talley et al.	
	14	5972986		1999-10-26	Seibert et al.	
	15	6156781		2000-12-05	Talley et al.	
	16	6294192		2001-12-25	Patel et al.	
	17	6342249		2002-01-29	Wong et al.	
	18	6368626		2002-04-09	Bhatt et al.	
	19	6420394		2002-07-16	Supersaxo, A.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10541216
Filing Date	2005-06-29
First Named Inventor	Mark Tawa
Art Unit	1615
Examiner Name	Eric Silverman
Attorney Docket Number	TPIP017D/WO US

20	6579895		2003-06-17	Karim et al.	
----	---------	--	------------	--------------	--

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S.PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020006951		2002-01-17	Hageman et al.	
	2	20020107250		2002-08-08	Hariharan et al.	
	3	20040154890		2004-08-12	Liu, Jintao	
	4	20040242640		2004-12-02	Desai et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

**FOREIGN PATENT DOCUMENTS**

Remove

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	00/32189	WO		2000-06-08	G. D. SEARLE & CO.		<input type="checkbox"/>
	2	01/41536	WO		2001-06-14	PHARMACIA CORPORATION		<input type="checkbox"/>

/Renee Claytor/

12/21/2009

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10541216
Filing Date		2005-06-29
First Named Inventor	Mark Tawa	
Art Unit		1615
Examiner Name	Eric Silverman	
Attorney Docket Number		TPIP017D/WO US

3	01/41760	WO		2001-06-14	PHARMACIA CORPORATION		<input type="checkbox"/>
4	01/42221	WO		2001-06-14	PHARMACIA CORPORATION		<input type="checkbox"/>
5	01/42222	WO		2001-06-14	PHARMACIA CORPORATION		<input type="checkbox"/>
6	01/45706	WO		2001-06-28	PHARMACIA CORPORATION		<input type="checkbox"/>
7	01/51919	WO		2001-07-19	TRANSFORM PHARMACEUTICALS, INC.		<input type="checkbox"/>
8	01/78724	WO		2001-10-25	PHARMACIA CORPORATION		<input type="checkbox"/>
9	01/91750	WO		2001-12-06	PHARMACIA CORPORATION		<input type="checkbox"/>
10	02/00627	WO		2002-01-03	FAKO ILACLARI A.S.		<input type="checkbox"/>
11	02/56878	WO		2002-07-25	PHARMACIA CORPORATION		<input type="checkbox"/>
12	02/102376	WO		2002-12-27	PHARMACIA CORPORATION		<input type="checkbox"/>
13	95/23596	WO		2006-11-08	THE BOOTS COMPANY PLC AGGARWAL		<input type="checkbox"/>

/Renee Claytor/

12/21/2009

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10541216
Filing Date		2005-06-29
First Named Inventor	Mark Tawa	
Art Unit	1615	
Examiner Name	Eric Silverman	
Attorney Docket Number	TPIP017D/WO US	

14	1167355	EP		2003-10-01	FAKO ILACLARi A.S.		<input type="checkbox"/>
15	05/053612	WO		2005-06-16	Shire Laboratories, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button **Add**

**NON-PATENT LITERATURE DOCUMENTS**

**Remove**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Database, WPI, Section Ch, Week 197936, Derwent Publications Ltd., London, GB, Class B02, AN 1979-65538B XP002282989 & JP 54 095589 A (Sumitomo) 1979 abstract	<input type="checkbox"/>
	2	Davies et al., Clin. Pharmacokinet., 38: 225-242 (2000)	<input type="checkbox"/>
	3	Fitzgerald, Garret A., "The Coxibs, Selective Inhibitors of Cyclooxygenase-2", New England Journal of Medicine, Vol. 345, No. 6, August 9, 2001	<input type="checkbox"/>
	4	Fung et al., Solvent Effects on Comparative Dissolution of Pharmaceutical Solvates, Chem. Farm. Bull., 22(2), pgs. 454-458 (1974)	<input type="checkbox"/>
	5	Rubino et al., Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs", Int. J. of Pharma., 65, pgs. 141-145 (1990)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Renee Claytor/

12/21/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10541216
Filing Date	2005-06-29
First Named Inventor	Mark Tawa
Art Unit	1615
Examiner Name	Eric Silverman
Attorney Docket Number	TPIP017D/WO US

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

/Renee Claytor/

12/21/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10541216
Filing Date	2005-06-29
First Named Inventor	Mark Tawa
Art Unit	1615
Examiner Name	Eric Silverman
Attorney Docket Number	TPIP017D/WO US

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paul Burgess/	Date (YYYY-MM-DD)	2006-11-17
Name/Print	Paul Burgess	Registration Number	53852

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

/Renee Claytor/

12/21/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

/Renee Claytor/

12/21/2009